Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

BACKGROUND: Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Nabors, L. Burt, Fink, Karen L., Mikkelsen, Tom, Grujicic, Danica, Tarnawski, Rafal, Nam, Do Hyun, Mazurkiewicz, Maria, Salacz, Michael, Ashby, Lynn, Zagonel, Vittorina, Depenni, Roberta, Perry, James R., Hicking, Christine, Picard, Martin, Hegi, Monika E., Lhermitte, Benoit, Reardon, David A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2015
Ämnen:
Clinical Investigations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482861/
https://ncbi.nlm.nih.gov/pubmed/25762461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou356
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk